Prognostic parameters in uveal melanoma and their association with bap1 expression

British Journal of Ophthalmology

Volumn 98, Issue 12, 2014, Pages 1738-1743

  Van Essen, T Huibertus ^a   Van Pelt, Sake ^a   Versluis, Mieke ^a   Bronkhorst, Inge H G ^a   Van Duinen, Sjoerd G ^a   Marinkovic, Marina ^a   Kroes, Wilma G M ^a   Ruivenkamp, Claudia A L ^a   Shukla, Shruti ^a   De Klein, Annelies ^b   Kiliç, Emine ^b   Harbour, J William ^c   Luyten, Gregorius P M ^a   Van Der Velden, Pieter A ^d   Verdijk, Rob M ^b   Jager, Martine J ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; PROTEIN BAP1; UNCLASSIFIED DRUG; BAP1 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN; UBIQUITIN THIOLESTERASE;

ADULT; AGED; ARTICLE; BAP1 GENE; CANCER PROGNOSIS; CARCINOGENESIS; CAUSE OF DEATH; CHROMOSOME 3; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENUCLEATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ASSOCIATION; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; METASTASIS; MONOSOMY; MORTALITY; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TUMOR VOLUME; UVEA MELANOMA; VERY ELDERLY; ENZYME IMMUNOASSAY; GENETICS; MELANOMA; METABOLISM; MIDDLE AGED; PROGNOSIS; UVEAL NEOPLASMS;

ADULT; AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 3; EYE ENUCLEATION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MELANOMA; MIDDLE AGED; MONOSOMY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN THIOLESTERASE; UVEAL NEOPLASMS;

EID: 84911451920     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305047     Document Type: Article

References (47)

1. Mooy CM, de Jong PT. Prognostic parameters in uveal melanoma: a review. Surv Ophthalmol 1996;41:215-28.
2. Kujala E, Damato B, Coupland SE, et al. Staging of ciliary body and choroidal melanomas based on anatomic extent. J Clin Oncol 2013;31:2825-31.
3. Kivela T, Kujala E. Prognostication in eye cancer: the latest tumor, node, metastasis classifi cation and beyond. Eye (Lond) 2013;27:243-52.
4. Aronow M, Sun Y, Saunthararajah Y, et al. Monosomy 3 by FISH in uveal melanoma: variability in techniques and results. Surv Ophthalmol 2012;57:463-73.
5. van den Bosch T, van Beek JG, Vaarwater J, et al . Higher percentage of FISH-determined monosomy 3 and 8q ampli fication in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci 2012;53:2668-74.
6. Damato B, Dopierala JA, Coupland SE. Genotypic profi ling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 2010;16:6083-92.
7. Coupland SE, Lake SL, Zeschnigk M, et al. Molecular pathology of uveal melanoma. Eye (Lond) 2013;27:230-42.
8. White VA, Chambers JD, Courtright PD, et al. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998;83:354-9.
9. Prescher G, Bornfeld N, Becher R. Nonrandom chromosomal abnormalities in primary uveal melanoma. J Natl Cancer Inst 1990;82:1765-9.
10. Prescher G, Bornfeld N, Hirche H, et al. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996;347:1222-5.
11. Abdel-Rahman MH, Cebulla CM, Verma V, et al. Monosomy 3 status of uveal melanoma metastases is associated with rapidly progressive tumors and short survival. Exp Eye Res 2012;100:26-31.
12. Kilic E, van GW, Lodder E, et al. Clinical and cytogenetic analyses in uveal melanoma. Invest Ophthalmol Vis Sci 2006;47:3703-7.
13. van Beek JG, Koopmans AE, Vaarwater J, et al. The prognostic value of extraocular extension in relation to monosomy 3 and gain of chromosome 8q in uveal melanoma. Invest Ophthalmol Vis Sci 2014;55:1284-91.
14. Ewens KG, Kanetsky PA, Richards-Yutz J, et al . Genomic profile of 320 uveal melanoma cases: chromosome 8p-loss and metastatic outcome. Invest Ophthalmol Vis Sci 2013;54:5721-9.
15. Damato B, Coupland SE. Translating uveal melanoma cytogenetics into clinical care. Arch Ophthalmol 2009;127:423-9.
16. Harbour JW. Molecular prognostic testing and individualized patient care in uveal melanoma. Am J Ophthalmol 2009;148:823-9.
17. Scholes AG, Damato BE, Nunn J, et al. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003;44:1008-11.
18. Mudhar HS, Parsons MA, Sisley K, et al. A critical appraisal of the prognostic and predictive factors for uveal malignant melanoma. Histopathology 2004;45:1-12.
19. Tschentscher F, Husing J, Holter T, et al. Tumor classifi cation based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 2003;63:2578-84.
20. Onken MD, Worley LA, Ehlers JP, et al. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 2004;64:7205-9.
21. Jensen DE, Proctor M, Marquis ST, et al. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene 1998;16:1097-112.
22. Scheuermann JC, de Ayala Alonso AG, Oktaba K, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010;465:243-7.
23. Ventii KH, Devi NS, Friedrich KL, et al. BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Res 2008;68:6953-62.
24. Carbone M, Yang H, Pass HI, et al. BAP1 and cancer. Nat Rev Cancer 2013;13:153-9.
25. Aoude LG, Vajdic CM, Kricker A, et al. Prevalence of germline BAP1 mutation in a population-based sample of uveal melanoma cases. Pigment Cell Melanoma Res 2013;26:278-9.
26. Laurent C, Gentien D, Piperno-Neumann S, et al. Patient-derived xenografts recapitulate molecular features of human uveal melanomas. Mol Oncol 2013;7:625-36.
27. Harbour JW, Onken MD, Roberson ED, et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010;330:1410-13.
28. Onken MD, Worley LA, Tuscan MD, et al. An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. J Mol Diagn 2010;12:461-8.
29. McLean IW, Foster WD, Zimmerman LE, et al. Modifications of Callender's classifi cation of uveal melanoma at the Armed Forces Institute of Pathology. Am J Ophthalmol 1983;96:502-9.
30. Maat W, Jordanova ES, van Zelderen-Bhola SL, et al. The heterogeneous distribution of monosomy 3 in uveal melanomas: implications for prognostication based on fi ne-needle aspiration biopsies. Arch Pathol Lab Med 2007;131: 91-6.
31. Bronkhorst IH, Maat W, Jordanova ES, et al. Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma. Arch Pathol Lab Med 2011;135:1042-7.
32. Koopmans AE, Verdijk RM, Brouwer RW, et al. Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol Published Online First: 14 Mar 2014. doi:10.1038/modpathol.2014.43
33. Bengtsson H, Simpson K, Bullard J, et al. aroma.affymetrix: A generic framework in R for analyzing small to very large Affymetrix data sets in bounded memory. Tech Report #745, Berkeley: Department of Statistics, University of California, 2012.
34. Bengtsson H, Irizarry R, Carvalho B, et al. Estimation and assessment of raw copy numbers at the single locus level. Bioinformatics 2008;24:759-67.
35. Bengtsson H, Wirapati P, Speed TP. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 2009;25:2149-56.
36. Smyth GK. In: Gentleman R, Carey V, Dudoit S, Irizarry R, Huber W, eds. Bioinformatics and computational biology solutions using {R} and bioconductor. New York: Springer, 2005:397-420.
37. Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics 2008;24:1547-8.
38. Du P, Zhang X, Huang CC, et al. Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 2010;11:587.
39. Du P, Kibbe WA, Lin SM. nuID: a universal naming scheme of oligonucleotides for illumina, affymetrix, and other microarrays. Biol Direct 2007;2:16.
40. Lin SM, Du P, Huber W, et al. Model-based variance-stabilizing transformation for Illumina microarray data. Nucleic Acids Res 2008;36:e11.
41. th edn. New York: Springer, 2010:547-60.
42. van Gils W, Lodder EM, Mensink HW, et al. Gene expression profiling in uveal melanoma: two regions on 3p related to prognosis. Invest Ophthalmol Vis Sci 2008;49:4254-62.
43. Meir T, Zeschnigk M, Masshofer L, et al. The spatial distribution of monosomy 3 and network vasculogenic mimicry patterns in uveal melanoma. Invest Ophthalmol Vis Sci 2007;48:1918-22.
44. Onken MD, Lin AY, Worley LA, et al. Association between microarray gene expression signature and extravascular matrix patterns in primary uveal melanomas. Am J Ophthalmol 2005;140:748-9.
45. Shah AA, Bourne TD, Murali R. BAP1 protein loss by immunohistochemistry: a potentially useful tool for prognostic prediction in patients with uveal melanoma. Pathology 2013;45:651-6.
46. Maat W, Ly LV, Jordanova ES, et al. Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma. Invest Ophthalmol Vis Sci 2008;49:505-10.
47. Worley L.A. , Onken M.D., Person E., et al. Transcriptomic versus chromosomal prognostic markers and clinical outcome in uveal melanoma.Clin Cancer Res2007;13:1466-71.